Diagnostic and clinical role of serum proteinase 3 antineutrophil cytoplasmic antibodies in inflammatory bowel disease

• Published in: Journal of gastroenterology and hepatology 2018-09, Vol.33 (9), p.1603-1607
• Main Authors: Takedatsu, Hidetoshi, Mitsuyama, Keiichi, Fukunaga, Shuhei, Yoshioka, Shinichiro, Yamauchi, Ryosuke, Mori, Atsushi, Yamasaki, Hiroshi, Kuwaki, Kotaro, Sakisaka, Hideto, Sakisaka, Shotaro, Torimura, Takuji
• Format: Article
• Language: English
• Subjects: Antineutrophil cytoplasmic antibodies; Chemiluminescence; Colon; Crohn's disease; Enzyme immunoassay; Granulomatosis; IBD: clinical trials; Immunoglobulins; immunology; Inflammatory bowel disease; Inflammatory bowel diseases; Intestine; microbiology and inflammatory bowel diseases; Minority & ethnic groups; Proteinase; Proteinase 3; screening and diagnosis; Ulcerative colitis
• ISSN: 0815-9319; 1440-1746
• DOI: 10.1111/jgh.14140

Background and Aim Proteinase 3 antineutrophil cytoplasmic antibodies (PR3‐ANCAs) are well‐known serological markers for granulomatosis with polyangiitis, but their role as serological markers for inflammatory bowel disease remains uncertain. The present study aimed to evaluate the diagnostic and clinical role of PR3‐ANCAs as markers for inflammatory bowel disease. Methods Using a new methodology with chemiluminescence enzyme immunoassay, serum PR3‐ANCA titers were assessed in 102 patients with ulcerative colitis (UC), 67 patients with Crohn's disease (CD), 44 controls with other intestinal diseases, and 66 healthy controls. Associations with clinical data were investigated. The diagnostic role of PR3‐ANCAs was evaluated by receiver operating characteristic analysis. Results Proteinase 3 antineutrophil cytoplasmic antibody titers were significantly higher in patients with UC than in those with CD patients, patients with intestinal diseases (intestinal controls), and healthy controls (all P